Hutchmed Share Price (HCM)

Have caught my eye:

1 NHS starting a trial a vaccine treatment for rectal cancer that has been resected. This is a long way from being a treatment, but could reduce the flow of patients into 2L /3L mCRC. I suspect as it is an individualised vaccine it will be £££.

2 NICE has refused to endorse Enhertu for certain breast cancer patients despite efficacy, it says the price is too high. With a quality adjusted life year value of £20-30k that NICE wants to achieve this is an effective cap on UK cancer treatment costs. This will then flow into other European value assessments. Takeda will be moving into European markets with Fruq in H2, it shows there may be some pricing issues and delays in take up as governments do their value assessments.

I mention these for interest and examples of potential competition and commercialisation issues ahead…..

Updates include

Takeda sales

Changes to registration studies

More detail on some of the late stage assets in development.

Sustainability measures.

Guess who..2500..

Innovent, Beigene also down…..sectoral and not very specific to HCM

The publication of Frutiga suggests it is strong science…..the approval in China should be not too long in coming….

in the meantime…time to consider topping up….this approval and the Sovlep first approval could both arrive before the HY results at the end of July….

Its proper text book stuff this, every time there's positive news (today) prop traders try to squash sentiment by pushing it down, Hang Seng currently up by 2.3%

Hutchmed was down 3% at one point, same mo' as results and following updates..